More Insights On Upstream Manufacturing


  • Preclinical Immunogenicity Risk Assessment of Biotherapeutics

    Among the primary causes for attrition in early clinical development are safety and pharmacology issues. In the case of biopharmaceuticals, immunogenic and hypersensitivity reactions are perhaps the largest contributors to such early clinical failures

  • Developability of Biotherapeutic Candidates, Reducing the Risk of Failure

    It is estimated that only one out of every 1,000 preclinical candidates reaches the commercial market. The ability to assess the “developability” of a therapeutic candidate in late discovery through clinical phases of development can be an extremely powerful tool to enhance the chance of clinical success. Screening of potential candidates in the discovery process will help to reduce costs, risk (attrition) and overall development time.  Being able to assess the manufacturability and safety of the drug candidate, before large investments are made, allows companies to focus on the most promising candidate and maximize R&D spending.

  • Assay Workflow Automation: Liquid Handling, Reading and Imaging Together

    Thanks for your interest in BioSpa™ 8 Automated Incubator. We are excited to share the following product demonstrations with you so you can see how BioSpa links liquid handling, reading and imaging together for unattended workflow automation. We’ll provide examples of typical assay workflows to help you understand exactly how BioSpa can help you take control of your cell assays.

More Upstream Manufacturing Webinars